Caribou Biosciences to Participate in Upcoming Investor Conferences

Rhea-AI Summary

Caribou Biosciences (Nasdaq: CRBU), a clinical-stage CRISPR genome-editing biopharmaceutical company, has announced its upcoming participation in two major investor conferences. Rachel Haurwitz, PhD, the company's president and CEO, will be featured in fireside chats at both events.

The schedule includes:

• H.C. Wainwright 3rd Annual Cell Therapy Virtual Conference on February 25, 2025, at 11:30 AM ET
• Leerink Global Healthcare Conference on March 11, 2025, at 1:40 PM ET

Both presentations will be available via webcast on the company's website, accessible for at least 30 days following each event.

News Market Reaction – CRBU

+0.70%

+0.70% Session move

In the trading session that priced this news, CRBU gained 0.70%, reflecting a mild positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

BERKELEY, Calif., Feb. 18, 2025 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced Rachel Haurwitz, PhD, Caribou’s president and chief executive officer, will participate in the following investor conferences:

• H.C. Wainwright 3rd Annual Cell Therapy Virtual Conference
  February 25, 2025, fireside chat at 11:30 AM ET
  Webcast

• Leerink Global Healthcare Conference
  March 11, 2025, fireside chat at 1:40 PM ET
  Webcast

For more information, visit the Events page on Caribou’s website. Webcasts will be available on the Caribou website for at least 30 days after the event.

About Caribou Biosciences, Inc.
Caribou Biosciences is a clinical-stage CRISPR genome-editing biopharmaceutical company dedicated to developing transformative therapies for patients with devastating diseases. The company’s genome-editing platform, including its Cas12a chRDNA technology, enables superior precision to develop cell therapies that are armored to potentially improve activity against disease. Caribou is advancing a pipeline of off-the-shelf cell therapies from its CAR-T platform to offer broad access and rapid availability of treatments for patients with hematologic malignancies and autoimmune diseases. Follow us @CaribouBio and visit www.cariboubio.com.

Caribou Biosciences, Inc. contacts:
Investors:
Amy Figueroa, CFA
investor.relations@cariboubio.com 

Media:
Peggy Vorwald, PhD
media@cariboubio.com 

FAQ

When is Caribou Biosciences (CRBU) presenting at the H.C. Wainwright Cell Therapy Conference 2025?

Caribou Biosciences will present at the H.C. Wainwright Cell Therapy Virtual Conference on February 25, 2025, at 11:30 AM ET.

What upcoming investor conferences will CRBU participate in during Q1 2025?

CRBU will participate in two conferences: the H.C. Wainwright Cell Therapy Virtual Conference on February 25 and the Leerink Global Healthcare Conference on March 11, 2025.

How long will the CRBU conference webcasts be available for viewing?

The webcasts will be available on Caribou's website for at least 30 days after each event.

What time is Caribou Biosciences presenting at the Leerink Global Healthcare Conference 2025?

Caribou Biosciences will present at the Leerink Global Healthcare Conference on March 11, 2025, at 1:40 PM ET.